BRIEF

on SANOFI-AVENTIS (EPA:SAN)

Results from the XTEND-Kids study show the potential of ALTUVIIIO in severe hemophilia A

Stock price chart of SANOFI-AVENTIS (EPA:SAN) showing fluctuations.

Sanofi-Aventis announces the publication, in the New England Journal of Medicine, of phase III data from the XTEND-Kids study. The results show that ALTUVIIIO, administered once a week, achieves sustained levels of factor VIII expression in children with severe hemophilia A. The drug provides effective protection against bleeding, without the development of factor VIII inhibitors.

The study, involving 73 participants, found a median annualized bleeding rate of 0.00. No joint bleeding was observed in 82% of treated children, demonstrating the potential of ALTUVIIIO to sustainably protect joint health. ALTUVIIIO was well tolerated, with side effects mainly related to mild infections.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all SANOFI-AVENTIS news